Related Experiment Video

Updated: Jan 15, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.6K

Applying DanGer Shock Eligibility Criteria to a Real-World Cohort of Cardiogenic Shock Patients

Raffaela Miriam Planka1, Lukas Herold1, Theresa Glantschnig1

  • 1Department of Internal Medicine, Division of Cardiology, Medical University of Graz, Graz, Austria.

Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions
|October 13, 2025
PubMed

Insights

The DanGer Shock trial showed a microaxial flow pump reduced mortality in STEMI-related cardiogenic shock. However, few patients in a real-world registry met trial criteria, limiting generalizability.

Area of Science:

  • Cardiology
  • Interventional Cardiology

Background:

  • The DanGer Shock trial assessed microaxial flow pump use in ST-elevation myocardial infarction (STEMI)-related cardiogenic shock (CS).
  • The trial found improved 180-day survival with the pump alongside standard therapy.

Purpose of the Study:

  • To evaluate the applicability of DanGer Shock trial eligibility criteria within a real-world registry.
  • To compare characteristics and outcomes of patients meeting criteria versus the broader registry cohort.

Main Methods:

  • The PREPARE CardShock registry (N=721) was analyzed.
  • Patients with advanced CS (SCAI stages C-E) on vasoactive medication were included.
  • DanGer Shock eligibility criteria were retrospectively applied.

Main Results:

  • Only 30.5% of STEMI-CS patients (16.2% of total registry) met DanGer Shock criteria.
  • Eligible patients had higher baseline SBP and lactate, and more frequent resuscitation compared to trial participants.
  • 180-day mortality was significantly higher in eligible registry patients (71.8%) than in the DanGer Shock trial (52.1%).

Conclusions:

  • The DanGer Shock trial's strict eligibility criteria excluded a majority of real-world STEMI-CS patients.
  • Findings suggest DanGer Shock trial outcomes may not be broadly generalizable to all STEMI-CS patients.
  • Real-world data indicates a potential gap in treatment applicability for this high-risk population.
Abstract

Keywords:
AMICSMCSSTEMI‐related CScardiogenic shockmicroaxial flow pumpmortality

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.1K
Author Spotlight: Developing Innovative Therapeutic Strategies for Hemorrhagic Shock Research08:14

Author Spotlight: Developing Innovative Therapeutic Strategies for Hemorrhagic Shock Research

Published on: March 22, 2024

1.9K

Related Concept Videos

Cardiopulmonary Resuscitation III: AED Use01:23

Cardiopulmonary Resuscitation III: AED Use

Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...
530
Blood Pressure Imbalances and Circulatory Shock01:24

Blood Pressure Imbalances and Circulatory Shock

Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
1.5K
Introduction Cardiac Emergencies01:30

Introduction Cardiac Emergencies

Cardiac emergencies are critical situations involving the heart that require immediate medical intervention to prevent severe complications or death. These emergencies often arise from underlying heart conditions that impair the heart's ability to function correctly.Types of Cardiac EmergenciesThe most common types of cardiac emergencies include Acute Coronary Syndrome (ACS), myocardial infarction (MI), cardiac arrest, and heart failure.Acute Coronary Syndrome (ACS)Acute Coronary Syndrome (ACS)...
296
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
655
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
468
Relative Risk01:12

Relative Risk

Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
2.0K